Illustration by Natasha Wigoder.
An international Delphi consensus
The Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) 2025 Guidelines were developed through an international Delphi consensus process to identify the most important extra-pharmacological factors influencing psychedelic clinical trials. These factors - commonly referred to as “(mind)set and setting” - include the physical, social contexts in which psychedelic substances are administered. The ReSPCT Guidelines provide a standardized framework for reporting these contextual variables, aiming to support transparency, comparability, and rigour in psychedelic research. Researchers, clinicians, and trial designers are invited to use the guidelines, and explanatory materials to improve study design and reporting across the field.
Reference: Pronovost-Morgan C, Greenway KT, Roseman L & The ReSPCT Experts. An international Delphi consensus for reporting of setting in psychedelic clinical trials. Nature Medicine. 2025. https://www.nature.com/articles/s41591-025-03685-9 (doi:10.1038/s41591-025-03685-9)
We encourage study teams to report each item in publications of clinical trials involving psychedelic drugs, either in the main article or as supplementary information. The ReSPCT Guidelines Explained, introduction
Resources
Downloads
Explanatory document
Each of the 30 items explained, with suggested reporting questions, measurement tools and expert quotes from the Delphi process.
Printable checklist
A fillable, printable checklist of the 30 ReSPCT items to complete and submit alongside a psychedelic clinical trial publication.